Synopsys, Inc.

“Synopsys is a structurally irreplaceable compounder — EDA duopolist, 80%+ recurring revenue, foundry-certified chokepoint positioning, and now the dominant silicon-to-systems platform post-ANSYS — but at $524.74 (~37x normalized EV/FCF, $100.5B market cap), the price embeds perfection. The ANSYS acquisition introduces 4–5x EBITDA leverage and ROIC dilution that requires 5–7 years and clean execution to work through, while China (~25% of revenue) remains the single credible path to permanent impairment. A 20–30% pullback to the $370–$420 range would create a compelling entry; at current prices, new investors should track rather than initiate.”